Characterization and Preclinical Evaluation of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Chronic Lymphocytic Leukemia

被引：0
|
作者：
Tantawy, Shady I. [1 ]
Timofeeva, Natalia [1 ]
Fujiwara, Hitomi [2 ]
Hatakeyama, Mariko [2 ]
Herrera, Breana [1 ]
Loza, Lizbeth [1 ]
Asami, Tokiko [2 ]
Ohmoto, Hiroshi [2 ]
Miyamoto, Kyoko [3 ]
Nishioka, Yu [2 ]
Arimura, Akinori [3 ]
Sawa, Masaaki [2 ]
Jain, Nitin [4 ]
Gandhi, Varsha [1 ,4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[2] Carna Biosci Inc, Kobe, Hyogo, Japan
[3] CarnaBio USA Inc, San Francisco, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189659
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] PRECLINICAL CHARACTERIZATION OF THRX-113587: A NOVEL, POTENT AND SELECTIVE INHIBITOR FOR THE NOREPINEPHRINE TRANSPORTER
    Shen, F.
    Smith, J.
    Tsuruda, P.
    Stangeland, E.
    McNamara, A.
    Cremers, T.
    Martin, W.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 141 - 141
  • [42] Characterization of T-cell metabolic defects in chronic lymphocytic leukemia preclinical model
    Gamal, Wael
    Mediavilla-Varela, Melanie
    Maharaj, Kamira
    Uriepero, Angimar
    Kunta, Vishaal
    Sahakian, Eva
    Pinilla-Ibarz, Javier
    CANCER RESEARCH, 2023, 83 (07)
  • [43] Evaluation of the novel Bruton's tyrosine kinase (BTK) inhibitor GDC-0853 in chronic lymphocytic leukemia (CLL) with wild type or C4815 mutated BTK.
    Reiff, Sean David
    Guinn, Daphne
    Mantel, Rose
    Smith, Lisa
    Cheney, Carolyn
    Johnson, Amy J.
    Byrd, John C.
    Woyach, Jennifer Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor
    Yamakawa, Hiroko
    Mizutani, Akio
    Arikawa, Yasuyoshi
    Ebara, Shunsuke
    Satoh, Yoshihiko
    Morishita, Daisuke
    CANCER RESEARCH, 2022, 82 (12)
  • [45] Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor
    Yamakawa, Hiroko
    Mizutani, Akio
    Arikawa, Yasuyoshi
    Ebara, Shunsuke
    Satoh, Yoshihiko
    Morishita, Daisuke
    CANCER SCIENCE, 2023, 114 : 831 - 831
  • [46] Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models
    Ren, Yongxin
    Sun, Qiaoling
    Long, Jingwen
    Fan, Shiming
    Tang, Renxiang
    Zhang, Wei
    Ge, Xuelei
    Tang, Jianxing
    Wang, Linfang
    Shi, Dongxia
    Chen, Hongbo
    Cheng, Min
    Qing, Weiguo
    Su, Weiguo
    CANCER RESEARCH, 2017, 77
  • [47] BTK Inhibitor Ibrutinib/Zanubrutinib Plus Bendamustine and Rituximab As the Initial Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia : a Single Arm Real-World Study
    Zhu, Huayuan
    Wu, Wei
    Sha, Yeqin
    Jin, Ze
    Yang, Yilian
    Qiu, Jingyan
    Ding, Chongyang
    Wang, Zhen
    Shi, Chuanbing
    Peng, Chen
    Mi, Hongling
    Chen, Ruize
    Wang, Li
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    BLOOD, 2021, 138
  • [48] Targeting TLR signaling in chronic lymphocytic leukemia with a selective IRAK-4 inhibitor
    Gimenez, Neus
    Rosich, Laia
    Lee, Eriong
    Higashi, Morihiro
    Aymerich, Marta
    Lopez-Guerra, Monica
    Campo, Elias
    Colomer, Dolors
    LEUKEMIA & LYMPHOMA, 2017, 58 : 59 - 60
  • [49] Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL-Rearranged Leukemia
    Pollock, Roy M.
    Daigle, Scott R.
    Therkelsen, Carly A.
    Basavapathruni, Aravind
    Jin, Lei
    Allain, Christina J.
    Klaus, Christine R.
    Raimondi, Alejandra
    Scott, Margaret Porter
    Chesworth, Richard
    Moyer, Mikel P.
    Copeland, Robert A.
    Richon, Victoria M.
    Olhava, Edward J.
    BLOOD, 2012, 120 (21)
  • [50] ACALABRUTINIB, A SECOND-GENERATION BRUTON TYROSINE KINASE (BTK) INHIBITOR, IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Wierda, W.
    Jones, J.
    Furman, R.
    Stephens, D.
    Devereux, S.
    Brown, J.
    Hillmen, P.
    Hamdy, A.
    Fardis, M.
    Tawashi, M.
    Wang, M. H.
    Patel, P.
    Mittag, D.
    Krantz, F.
    Rothbaum, W.
    Izumi, R.
    O'Brien, S.
    Byrd, J.
    HAEMATOLOGICA, 2016, 101 : 151 - 151
12345